Serum LAPTM4B as a Potential Diagnostic and Prognostic Biomarker for Breast Cancer

Figure 1

Flow chart of patients and healthy controls recruited to the study. For the diagnostic serum study, blood samples were collected from primary breast cancer patients (), benign breast disease (), and healthy controls () attending Beijing Cancer Hospital. For the monitoring study, patients who had received adjuvant therapy were enrolled, and their blood samples were collected before and after treatment (). In addition, patients undergoing their adjuvant cycles in Beijing Cancer hospital were selected for efficacy evaluation (), containing 33 HER2-positive patients receiving trastuzumab therapy.